{"filings":[{"id":1341923,"accession_number":"0001856725-26-000003","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-06-29T22:54:48+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.","Maestas previously CFO of Tempest Therapeutics; base salary $500,000, target bonus 75%.","Maestas receives inducement option for 2,000,000 shares vesting over 4 years.","Board approved 2026 Equity Inducement Plan reserving 5,500,000 shares for new hires.","Plan allows inducement grants under Nasdaq Rule 5635(c)(4) without stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":730679,"accession_number":"0001193125-26-245636","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-28T22:12:37+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics shareholders elect all 7 directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All director nominees elected with >57M votes each; Jean-Luc Butel had highest withhold (4,997,042).","Ratification of CBIZ CPAs as auditor for FY2026 passed with 77,019,828 for, 332,645 against, 54,190 abstain.","Record date had 99,812,515 Class A and 23,970,359 Class B shares outstanding, voting together as a single class."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":676801,"accession_number":"0001193125-26-239977","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-27T00:41:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $20M via common stock and pre-funded warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 12.48M shares at $1.07/share and pre-funded warrants for 6.21M shares at $1.0699.","Gross proceeds of ~$20M; closing expected May 27, 2026.","Placement agents: H.C. Wainwright & Co. and Chardan Capital Markets; lock-up agreements for 60 days.","Offering made under effective S-3 registration statement filed August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470798,"accession_number":"0001193125-26-226691","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-15T20:08:23+00:00","items":["2.02","3.01","5.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.","Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.","CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.","Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.","Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110096,"accession_number":"0001193125-26-126240","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports Q4 net loss of $9.1M; announces up to $1.085B Chugai collaboration and $60.3M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.","Raised $60.3M via oversubscribed private placement led by Samsara BioCapital, including $6.0M debt conversion.","Initiated Phase 1 study of RT-114 (oral GLP-1/GLP-2 dual agonist) via RaniPill for obesity in December 2025.","Cash and equivalents $49.7M as of Dec 31, 2025; expected to fund operations into Q4 2027, including Chugai milestone.","Net loss for FY2025 was $41.0M, narrowed from $56.6M in FY2024; R&D expenses decreased 24% to $20.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110095,"accession_number":"0001193125-26-001098","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.02","3.03","5.03","5.07","9.01"],"status":"ready","headline":"Rani Therapeutics terminates TRA, adopts governance changes reducing Class B voting to 1 vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Tax Receivable Agreement with InCube Labs; no payments or early termination fees required.","Amended charter reduces Class B common stock voting power from 10 to 1 vote per share.","Eliminated stockholder written consent, classified board; added supermajority vote to amend bylaws.","Changes approved by majority holder written consent on Nov 24, 2025; effective Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126656,"accession_number":"0001193125-25-269722","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports Q3 2025 results, announces $1.085B Chugai collaboration and $60.3M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.","Closed $60.3M oversubscribed private placement led by Samsara BioCapital with participation from RA Capital, Anomaly, Special Situations Funds, and Invus.","Appointed Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board of Directors.","Cash runway expected into 2028; Phase 1 trial of oral obesity therapy RT-114 planned by end of 2025.","Net loss for Q3 2025 was $7.9M, improved from $12.7M in prior year period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126655,"accession_number":"0001193125-25-250614","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Rani Therapeutics closes private placement of 42.6M shares and warrants; board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 42,633,337 shares of Class A common stock, warrants to purchase 125,000,004 shares, and pre-funded warrants for 82,366,667 shares.","Post-closing shares outstanding: 97,541,221.","Directors Andrew Farquharson and Maulik Nanavaty resigned effective closing; no disagreement cited.","Abraham Bassan (Samsara BioCapital) and Vasudev Bailey (Anomaly Ventures) appointed as directors.","Samsara and Anomaly each have board designation rights while holding at least 25% of securities issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126654,"accession_number":"0001193125-25-241963","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).","Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.","Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.","Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.","Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143427,"accession_number":"0000950170-25-104998","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.","Cash, equivalents and marketable securities fell to $10.2M as of June 30, 2025 from $27.6M at Dec 31, 2024.","Entered research collaboration with Chugai for two undisclosed molecules; bioequivalence to subcutaneous delivery confirmed.","Warrant inducement transaction yielded $4.3M gross proceeds; registered direct offering raised $3.0M.","Phase 1 trial of oral GLP-1/GLP-2 agonist RT-114 for obesity expected to start H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143426,"accession_number":"0001193125-25-159793","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $3.0M via stock and warrant offering; suspends ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered securities purchase agreement to issue 4.354M shares and 3.146M pre-funded warrants at $0.40/share.","Gross proceeds expected to be ~$3.0M; closing expected on July 16, 2025.","Suspended its Controlled Equity Offering ATM program with H.C. Wainwright.","Directors and officers entered into 45-day lock-up agreements.","Placement agent Maxim Group LLC receives 5.25% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161607,"accession_number":"0000950170-25-090384","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).","Must regain compliance by December 17, 2025 by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period, subject to meeting other initial listing standards.","Company will monitor bid price and consider options, including a potential reverse stock split.","No assurance that the company will regain compliance or that Nasdaq will grant an extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161606,"accession_number":"0000950170-25-078949","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics annual meeting elects 7 directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees (Talat Imran, Mir Imran, Ausiello, Butel, Farquharson, Nanavaty, Rometty) elected; ~229.4M for each.","Ratification of CBIZ CPAs P.C. as auditor for FY2025 passed with ~238.5M for, 417k against, 817k abstain.","Broker non-votes of ~10.0M shares on director elections; no broker non-votes on auditor ratification.","Annual meeting held May 28, 2025; record date April 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161605,"accession_number":"0001193125-25-122872","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.","Issues new Series D warrant for 13,160,172 shares at $0.65/sh, 5-year term, subject to stockholder approval.","Company must file resale registration statement for Series D shares within 45 days; seeks Nasdaq approval.","Maxim Group receives 5.25% cash fee on gross proceeds as financial advisor.","Proceeds to be used for working capital and general corporate purposes via Rani LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161604,"accession_number":"0000950170-25-070344","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.","Preclinical data show RT-114 (oral bispecific GLP-1/GLP-2 agonist) bioequivalent to subcutaneous PG-102 with 111% relative bioavailability.","Preclinical data also demonstrate oral semaglutide via RaniPill (RT-116) comparable to subcutaneous in bioavailability, PK, and weight loss.","Phase 1 clinical trial for RT-114 treating obesity expected to begin mid-2025.","R&D expenses decreased to $6.6M and G&A to $5.6M; contract revenue was $0.2M from evaluation services."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161603,"accession_number":"0000950170-25-064624","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.","Company has 180 calendar days, until October 28, 2025, to regain compliance by achieving MVLS >= $50M for 10 consecutive business days.","If noncompliance persists, Nasdaq may delist; Rani could appeal or apply to transfer to Nasdaq Capital Market.","Rani is considering actions to regain compliance but has not yet decided on a response.","There is no assurance of regaining compliance or meeting other listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161602,"accession_number":"0000950170-25-060586","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Laureen DeBuono retires from Rani Therapeutics board; committees reconstituted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laureen DeBuono resigned from Board effective April 24, 2025; no disagreement with company.","Board reconstituted Audit Committee: Rometty (Chair), Butel, Nanavaty; Compensation: Nanavaty (Chair), Ausiello.","Nominating and Governance Committee: Butel (Chair), Ausiello, Rometty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161601,"accession_number":"0000950170-25-052527","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rani Therapeutics auditor Marcum resigns; FY2024 report had going concern note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on April 7, 2025; Audit Committee accepted resignation.","FY2024 audit report included explanatory paragraph about substantial doubt regarding going concern.","New auditor CBIZ CPAs P.C. appointed effective April 7, 2025 for fiscal year 2025.","No disagreements or reportable events with Marcum during FY2024 or subsequent interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179732,"accession_number":"0000950170-25-047701","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.","Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.","Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.","Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.","Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196481,"accession_number":"0000950170-24-126753","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.","Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.","Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.","New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.","Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196480,"accession_number":"0001193125-24-237838","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics to raise ~$10M via stock/warrant offering; cancels prior warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Issuing 3M shares + pre-funded warrants for 333K shares + Series C warrants for 3.33M shares at $3.00 combined price.","Gross proceeds ~$10M; closing expected Oct 16, 2024.","Cancelling Series A warrants for 3.25M shares issued July 2024.","Placement agent Maxim Group LLC receives 5.25% fee.","Directors and officers enter 30-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212792,"accession_number":"0000950170-24-105509","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rani Therapeutics dismisses EY as auditor, appoints Marcum; EY's 2023 report had going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed as independent auditor on Sep 10, 2024; Marcum LLP appointed immediately.","EY's 2023 audit opinion included a going concern explanatory paragraph about substantial doubt.","No disagreements or reportable events in fiscal 2022, 2023, or subsequent interim period.","Letter from EY to SEC confirming agreement attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212791,"accession_number":"0000950170-24-091744","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics posts Q2 net loss of $13.4M; announces ProGen partnership for oral obesity drug RT-114","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.","Net loss of $13.4M for Q2 2024, compared to $18.7M in same period 2023; includes $4.1M stock-based compensation.","R&D expenses fell to $6.1M from $11.1M YoY, driven by workforce reduction and timing of preclinical/clinical studies.","Announced co-development partnership with ProGen for RT-114, an oral GLP-1/GLP-2 dual agonist, with 50/50 cost and revenue share.","Phase 1 study for RT-114 expected to start in 2025; completed $10.0M equity offering in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212790,"accession_number":"0001193125-24-182549","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $10M via registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from sale of 2.8M shares, 446,753 pre-funded warrants, and warrants for 6.5M shares.","Combined offering price $3.08 per share/warrant unit; warrants exercisable at $3.08 starting six months after closing.","Series A warrants expire 18 months from issuance; Series B warrants expire 5.5 years from issuance.","Directors and officers subject to 60-day lock-up; company restricted from issuing new securities for up to 60 days.","Closing expected July 23, 2024; Maxim Group acted as placement agent with 6% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212789,"accession_number":"0000950170-24-083284","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Rani Therapeutics decides not to pursue equity financing after investor talks","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Engaged in discussions with investors for a potential equity financing but elected not to proceed.","Decision based on evaluation of business development, cash position, outlook, and market conditions.","Company will continue to assess cash needs and may seek equity financing in the future.","No specific numbers or financial guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231836,"accession_number":"0001193125-24-166293","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.","ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.","Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.","Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.","Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231835,"accession_number":"0000950170-24-066552","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics announces annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held May 29, 2024; all eight director nominees elected with overwhelming support.","Nominees: Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Laureen DeBuono, Andrew Farquharson, Malik Nanavaty, Lisa Rometty.","Ernst & Young ratified as independent auditor for FY2024 with approx. 232M votes for, 16K against.","Class A and Class B shares voted together; Class B shares have ten votes per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231834,"accession_number":"0000950170-24-053527","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).","Net loss $14.8M for Q1 2024 vs $16.8M same quarter 2023; includes $3.9M stock-based comp.","R&D expense $7.6M (down $2.1M YoY) on lower compensation and third-party costs.","RT-111 (oral anti-IL-12/23 antibody) Phase 1 achieved high bioavailability, well-tolerated, no serious AEs.","Expects Phase 2 trial for RT-102 (osteoporosis) in 2024; RaniPill HC Phase 1 readiness H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250124,"accession_number":"0000950170-24-034153","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).","Positive topline Phase 1 data for RT-111 (oral anti-IL12/23 antibody): high bioavailability, well-tolerated, no serious adverse events.","Strategic restructuring: discontinued RT-101, paused RT-105/110, reduced workforce, cost savings extend cash runway into 2025.","Phase 2 trial of RT-102 (teriparatide for osteoporosis) to start in 2024; RaniPill HC ready for Phase 1 in H2 2024.","Preclinical data showed transenteric delivery of GLP-1 triagonist elicits rapid weight loss; successful oral delivery of Humira via RaniPill HC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250123,"accession_number":"0000950170-24-011011","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Rani announces positive Phase 1 topline results for oral ustekinumab biosimilar RT-111","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RT-111 achieved 84% bioavailability vs subcutaneous Stelara injection; higher Cmax and shorter Tmax observed.","No serious adverse events; mild transient AEs resolved without intervention; no participants withdrew.","Celltrion holds right of first negotiation to acquire worldwide rights to RT-111 after successful Phase 1.","This marks Rani's third successful Phase 1 trial using RaniPill technology; potential differentiated oral dosing for psoriasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267668,"accession_number":"0000950170-23-071478","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rani Therapeutics reprices stock options for executives to $2.84 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reducing exercise price of certain outstanding options to $2.84 per share (closing price on Dec 16, 2023).","CEO Talat Imran: 936,444 options repriced from $5.44-$19.56; CFO Svai Sanford: 313,558 options from $5.44-$13.21.","CSO Mir Hashim: 328,374 options repriced from $5.44-$13.21; all options retain original vesting schedules and expiration dates.","Repricing covers employees, named executive officers, consultants, and non-employee directors; no other terms modified.","Board determined repricing best for retention and incentivization without cash outlay or additional equity dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267667,"accession_number":"0000950170-23-070230","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rani Therapeutics announces preclinical data on oral triagonist and updates on pipeline milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical study of incretin triagonist (GLP-1, GIP, glucagon) showed similar weight loss and lipid reduction via endoscope vs SC; no serious adverse events.","RT-102 (teriparatide for osteoporosis) Phase 2 trial expected to start in 2024.","Topline results from RT-111 Phase 1 (ustekinumab biosimilar) expected Q1 2024.","RaniPill HC development expected ready for Phase 1 trials in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267666,"accession_number":"0000950170-23-061104","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.","CEO Talat Imran salary reduced from $520k to $100k through 2024 or until $50M is raised.","Strategic prioritization: discontinue RT-101, pause RT-105/RT-110, workforce cut ~25%.","RT-102 Phase 2 starts year-end 2023; RT-111 Phase 1 topline expected Q1 2024; RaniPill HC Phase 1-ready 2H 2024.","RaniPill HC achieved >90% drug delivery success in preclinical studies with adalimumab and interleukin."],"consensus_eps_estimate":null,"consensus_eps_actual":1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267665,"accession_number":"0000950170-23-057420","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","2.02","2.05","9.01"],"status":"ready","headline":"Rani Therapeutics cuts workforce 25%, extends cash runway into 2025; reports preliminary Q3 net loss $17-19M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.","Cash, cash equivalents and marketable securities ~$60.5M at Sept 30, 2023; cash runway extended into 2025.","Preliminary Q3 net loss $17-19M (vs $16.2M in Q3 2022); nine-month net loss $53-55M.","RT-102 Phase 2 starts Q4 2023; RT-111 Phase 1 topline Q1 2024; RaniPill HC Phase 1-ready H2 2024.","RT-101 discontinued; RT-105 and RT-110 paused; new 33,340 sq ft lease in Fremont at $95,019/month base rent."],"consensus_eps_estimate":null,"consensus_eps_actual":1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267664,"accession_number":"0000950170-23-055005","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics reports positive preclinical safety data for RaniPill capsule in 60-day GLP study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60-day repeat administration in healthy animals showed no treatment-related adverse events; all animals remained healthy.","Study evaluated RT-100 (RaniPill with mannitol) vs. mock capsule; supports safety for clinical trials.","Data enable launch of longer-term trials including Phase II study of RT-102 for osteoporosis planned for 2023.","RaniPill platform is drug-agnostic, aiming to replace injections for biologics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284873,"accession_number":"0000950170-23-047058","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani reports 90% success in preclinical RaniPill HC studies; Phase 1 of adalimumab planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RaniPill HC delivered teriparatide in 18/20 administrations across two canine studies, a 90% cumulative success rate.","Payload increased to up to 20 mg, enabling oral delivery of 90+ additional drug candidates.","Fe57 study showed drug absorption comparable to subcutaneous injection.","Next milestone: initiate Phase 1 trial of RT-105 (adalimumab) using RaniPill HC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284872,"accession_number":"0000950170-23-041838","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q2 2023 net loss $18.7M; cash $74.6M; expands Celltrion partnership","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M for Q2 2023, up from $16.0M in Q2 2022; cash and securities $74.6M (down from $98.5M at YE 2022).","Expanded Celltrion partnership to develop RT-105 (adalimumab biosimilar) using high-capacity RaniPill HC device.","Appointed Kate McKinley as Chief Business Officer, bringing 20 years of biopharma experience.","Plan to initiate Phase 2 for RT-102 and Phase 1 for RT-111 (monoclonal antibody) in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304671,"accession_number":"0000950170-23-026234","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Rani Therapeutics enters exclusive worldwide license with Celltrion for oral adalimumab biosimilar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rani obtains exclusive, worldwide, royalty-free license to Celltrion IP for oral adalimumab biosimilar via Rani's delivery technology.","Celltrion will exclusively supply adalimumab biosimilar to Rani, with limited alternative sourcing rights if supply is disrupted.","Rani has sole manufacturing, development, and commercialization rights; Celltrion gets right of first negotiation after Phase 1 data.","Celltrion may terminate if development milestones not met; Rani can terminate for convenience with notice.","No financial terms disclosed; agreement covers IP ownership and mutual indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304670,"accession_number":"0000950170-23-024817","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics annual meeting elects all director nominees; ratifies Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected with substantial support; votes for each exceeded 226M, with withheld votes under 200K.","Ratification of Ernst & Young as independent auditor passed: 230,587,049 for, 51 against, 2,301 abstain.","Record date March 30, 2023: 25.4M Class A shares (1 vote each) and 24.1M Class B shares (10 votes each) outstanding.","No other proposals were considered; all matters approved as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304669,"accession_number":"0000950170-23-020539","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss $16.8M; Celltrion partnership and FDA feedback on RT-102","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.8M for Q1 2023, up from $13.8M in Q1 2022; non-cash stock compensation $4.0M.","Cash and equivalents $86.8M as of Mar 31, 2023; expected to fund operations to mid-2024.","Announced partnership with Celltrion to develop RT-111, an oral ustekinumab biosimilar.","FDA preliminary feedback supports 505(b)(2) pathway for RT-102 (osteoporosis); Phase 2 expected 2H 2023.","Three Phase 1 studies expected in 2023: RT-111, RT-105 (adalimumab biosimilar), RT-110 (parathyroid hormone)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304668,"accession_number":"0000950170-23-011909","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Lyn Baranowski will not stand for re-election at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lyn Baranowski notified Rani Therapeutics she will not stand for re-election at the 2023 annual meeting.","She will cease to be a board member and member of Compensation and Nominating/Governance committees effective at the meeting.","Decision not due to any disagreement with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324229,"accession_number":"0000950170-23-009162","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports FY2022 net loss $63.3M; cash $98.5M; RT-102 Phase 2 in H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.3M for 2022, vs $53.1M in 2021; cash $98.5M, sufficient to mid-2024.","Phase 1 data for RT-102 (osteoporosis) positive; FDA agrees 505(b)(2) pathway; Phase 2 planned H2 2023.","Partnership with Celltrion for RT-111 (ustekinumab biosimilar); exclusive license with right of first negotiation.","Expects to start three Phase 1 studies in 2023 for RT-105, RT-110, RT-111."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324228,"accession_number":"0000950170-23-000444","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Rani Therapeutics enters license/supply deal with Celltrion for oral ustekinumab biosimilar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rani obtains exclusive worldwide royalty-free license to Celltrion's ustekinumab biosimilar for oral delivery using Rani's platform.","Celltrion will supply the biosimilar; Rani must purchase exclusively from Celltrion unless supply disruption.","Celltrion has right of first negotiation for commercialization after Phase 1 data package; 30-day exercise, 90-day negotiation.","Rani owns all data from research and development; can terminate for convenience; Celltrion can terminate if milestones not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324227,"accession_number":"0000950170-23-000239","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Rani Therapeutics reports ~$99M cash; FDA feedback supports 505(b)(2) pathway for RT-102; Phase 2 in H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, restricted cash equivalents and marketable securities of ~$99M as of Dec 31, 2022, subject to audit.","FDA pre-IND feedback indicates 505(b)(2) pathway suitable for RT-102 (oral PTH analog for osteoporosis); Phase 2 trial expected H2 2023.","Positive topline Phase 1 repeat-dose results for RT-102 announced in Dec 2022, meeting all endpoints.","Plans to initiate three additional Phase 1 studies in 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypoparathyroidism), RT-111 (ustekinumab biosimilar)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342167,"accession_number":"0000950170-22-027117","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Rani Therapeutics draws $15M second tranche under $45M loan facility with Avenue Venture","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed $15M draw on Dec 29, 2022, as second tranche of $30M committed under Aug 8, 2022 Loan Agreement.","Total facility provides up to $45M in term loans; $15M was funded at closing, $15M now drawn.","Loan from Avenue Venture Opportunities Fund; terms previously filed and unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342166,"accession_number":"0000950170-22-026089","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"RT-102 repeat-dose Phase 1 meets endpoints; 91% delivery success, high bioavailability, supports Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No serious adverse events; all 10 participants completed 7-day daily dosing.","RaniPill GO delivered PTH with 91% overall success; Day 7 success rate 100%.","RT-102 showed high PTH bioavailability vs subcutaneous injection in Part 1.","Company expects to initiate Phase 2 trial of RT-102 in osteoporosis in H2 2023.","Over 185 RaniPill capsules administered in clinical studies; platform advancing for multiple programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342165,"accession_number":"0000950170-22-024430","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.","Net loss of $16.2M compared to $28.7M in Q3 2021; R&D expenses $9.1M, G&A expenses $7.2M.","RT-102 Phase 1 Part 2 repeat-dose data expected in Q4 2022; positive Part 1 showed 300-400% greater bioavailability vs subcutaneous Forteo.","RT-111 (ustekinumab biosimilar) preclinical development announced; Phase 1 planned in 2023.","$30M committed loan from Avenue Venture Opportunities; up to $150M at-the-market equity offering program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342164,"accession_number":"0001193125-22-267186","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics launches RT-111 oral ustekinumab biosimilar; RT-102 data due Q4 2022; RT-109 halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical development started for RT-111, an oral ustekinumab biosimilar for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.","RT-102 Phase 1 Part 2 (repeat-dose) topline data expected in Q4 2022; Phase 2 planned for H2 2023.","In vivo studies with fully-autonomous RaniPill HC (high-capacity capsule) anticipated in Q4 2022.","Active development of RT-109 (human growth hormone) discontinued; Rani open to partnering opportunities.","Three additional Phase 1 studies targeted for 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypo-parathyroidism), and RT-111."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358947,"accession_number":"0001193125-22-229280","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Rani Therapeutics enters $150M ATM equity offering agreement with Cantor and H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $150M of Class A common stock may be sold at market prices on Nasdaq through agents Cantor Fitzgerald and H.C. Wainwright.","Agent compensation set at up to 3.0% of gross sales price per share sold.","Offering under effective shelf registration (Form S-3, effective Aug 10, 2022); prospectus supplement filed Aug 24, 2022.","Rani not obligated to sell any shares; agreement may be terminated by either party with 10 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358946,"accession_number":"0000950170-22-016489","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q2 net loss $16M; positive RT-102 Phase 1 results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive Phase 1 topline results for RT-102 (PTH capsule for osteoporosis): high bioavailability, well-tolerated, all endpoints met.","Completed debt financing up to $45M with Avenue Capital Group; $15M funded at closing; cash runway extended into mid-2024.","Cash and equivalents $97.2M at June 30, 2022 vs $117.5M at Dec 31, 2021.","Net loss of $16.0M in Q2 2022 vs $5.5M in Q2 2021; R&D expenses rose to $9.5M.","Near-term milestones: repeat-dose RT-102 results in Q4 2022, additional Phase 1 trial initiation in 2H 2022, pre-IND meeting with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-10T23:59:59+00:00|358946"}